European Commission Approves 177Lu Vipivotide Tetraxetan Plus ADT for Prostate Cancer Subset


177Lu vipivotide tetraxetan becomes first targeted radioligand treatment approved by the European Commission for prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

The European Commission approved 177Lu vipivotide tetraxetan (Pluvicto) plus androgen deprivation therapy plus or minus androgen receptor (AR) pathway inhibition for the treatment of patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC), according to a press release from Novartis.

The European Commission’s decision was based on findings from the phase 3 VISION trial (NCT03511664), which assessed treatment with 177Lu vipivotide tetraxetan plus best supportive care vs best supportive care alone. Data from the trial indicated that patients treated with 177Lu vipivotide tetraxetan experienced a 38% reduction in death, as well as a 60% statistically significant reduction in risk of radiographic disease progression or death vs best supportive care alone.

“Today’s approval of [177Lu vipivotide tetraxetan] by the European Commission marks a major milestone for patients with advanced prostate cancer who have few alternative treatments at this stage of their disease,” Haseeb Ahmad, European president of Novartis, said in the press release.

177Lu vipivotide was approved by the FDA in March 2022 for the treatment of patients with PSMA-positive mCRPCwho were previously treated with an AR pathway inhibitor and taxane-based chemotherapy. The approval was also based on phase 3 data from the VISION trial.


Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer. News release. Novartis. December 13, 2022. Accessed December 15, 2022.

Related Videos
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Related Content